Storia in 1 fonti

CORRECTING and REPLACING Zetagen Therapeutics Presents Phase 2a Results at ASCO for Investigational ZetaMet™ (Zeta BC 003) in Metastatic Breast Cancer Patients with Lytic Bone Lesions

Raccontata da

Timeline cronologica